☰

CuraCell AB

Connecting R&D, manufacturing and clinical sites for CC-38

Industry
Cell therapy (autologous TIL therapy)
Headquarters
Solna, Sweden
Public information as of
July 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of CuraCell AB's published strategy and is not endorsed by, or produced in cooperation with, CuraCell AB. Company website

Strategic priorities

CuraCell is preparing first-patient dosing in a Phase I/IIa trial of CC-38, an autologous Tumor-Infiltrating Lymphocyte (TIL) therapy for cold solid tumors, after the Paul-Ehrlich-Institut cleared the CTA in August 2025 under EU-CT-Number 2025-521227-70-00. The program is built around the CytoPLY platform, which targets T-cell expansion below seven days while preserving a TCR (T-cell receptor) repertoire that supports durable response.

The product is made in three countries: tumor biopsies collected at Krankenhaus Nordwest in Frankfurt, expanded at the Zellwerk GMP (Good Manufacturing Practice) facility in Berlin-Brandenburg, and infused back into the patient at the Frankfurt site, with the scientific and process-development base at Cancer Center Karolinska in Solna. Each batch is one patient, so the chain from biopsy to infusion has to hold to a tighter schedule than conventional biologic manufacturing.

EQT Foundation backs CuraCell as part of its 'Library of Hope' deep-science portfolio, and the foundation's evergreen structure tolerates the long timelines cell therapy requires. The same mandate sets a carbon-neutrality trajectory that intersects directly with the energy footprint of cleanroom and cryopreservation operations.

The immediate operational gap is the data path between these three sites. Today, sequencing data from Solna, expansion parameters from Berlin-Brandenburg, and clinical outcomes from Frankfurt sit in separate systems, and the PEI inspection schedule for the Phase I/IIa trial is a hard deadline for paperless batch records and Annex 11 (the EU GMP rule on computerised systems) compliance.

Challenges we see

  • Operations Manufacturing

    Coordinating biopsy, manufacturing and infusion on one schedule

    Tumor biopsies are collected in Frankfurt, expanded at Zellwerk in Berlin-Brandenburg under GMP, and returned for infusion at Frankfurt. The patient is the batch, and the timeline is set by the patient's pre-conditioning regimen.

    As the trial moves from its first cohort toward wider enrolment, the number of biopsy-to-infusion chains running in parallel grows, and scheduling drift between any one chain and the patient in pre-conditioning becomes a recurring risk rather than a one-off.

  • Digital Integration

    Connecting R&D sequencing data with manufacturing and clinical data

    High-throughput TCR sequencing data is generated at Cancer Center Karolinska in Solna, perfusion bioreactor parameters sit at Zellwerk in Berlin-Brandenburg, and clinical outcomes are recorded at the Frankfurt site. The three systems have no agreed data model.

    Without a shared definition of a batch, a patient and a sample across the three sites, the five-year longitudinal tracking the scientific case rests on is assembled by hand, which does not scale with the cohort.

  • Operations Manufacturing

    Seeing live batch progress at the manufacturing partner

    CuraCell relies on Zellwerk for GMP production, and the Head of CMC coordinates patient readiness based on batch reports issued after each run. Phase I/IIa enrolment schedules patient pre-conditioning against expected batch release.

    As trial enrolment grows, the gap between batch events on the line and the decisions that depend on them widens, and a separate monitoring view of the running process becomes the practical way to keep clinical and manufacturing on the same clock.

  • Compliance Regulatory

    Paperless batch records and Annex 11 readiness for PEI

    The PEI CTA approval in August 2025 (EU-CT-Number 2025-521227-70-00) starts an inspection cadence in which electronic batch records, audit trails, and GAMP5 (Good Automated Manufacturing Practice)-validated digital systems are now the expected baseline.

    Where batch and quality records still move between systems by hand, each manual transfer becomes a separate item to perform and to verify during an inspection, and the volume of those transfers scales with the number of sites and patients.

  • ESG Energy

    Tracking the energy footprint of cleanroom and cryopreservation

    EQT Foundation's portfolio mandate includes progress on climate resilience, and cleanroom operations together with cryogenic storage are the dominant energy consumers in the CC-38 process.

    Without per-batch or per-process energy data, the carbon position can only be reported periodically rather than managed, which slows the path to a credible ESG narrative for the foundation.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. A live view of T-cell expansion at the manufacturing partner

    T-cell expansion progress at Zellwerk reaches CuraCell through batch reports issued after the run, so the Head of CMC is making patient-scheduling decisions on information that is already several days old.

    An agreed, read-only data path from the Zellwerk bioreactor control systems into a monitoring view in Solna lets the CMC team compare the running batch against reference runs and flag drift while the cells are still expanding.

    • CuraCell, Phase I/IIa CTA approval, August 2025
    • EU Clinical Trials Register, EU-CT-Number 2025-521227-70-00

  2. Tracking TCR repertoire from biopsy to year five

    Sequencing data from Solna, expansion parameters from Berlin-Brandenburg, and clinical outcomes from Frankfurt are stored in separate systems with no agreed batch or patient identifier, so the longitudinal immunogenomic monitoring the scientific case depends on is assembled manually.

    An ontology-based platform that defines patient, sample, run and time point once, then loads each site's data against that model, makes the five-year TCR persistence question queryable across the three sites.

    • CuraCell Deep Research, Section 4.2 (Source to Scientist)
    • Lucas Arruda (CSO), quoted on longitudinal immunogenomic monitoring

  3. Paperless batch records for PEI inspections

    Records move between lab instruments, batch files and the batch record through manual transfers and re-keying, and each transfer is a separate step to verify during an inspection.

    Connecting laboratory instruments and the batch record so that results arrive with their own audit trail shortens the release path and makes the evidence chain readable from the record itself.

    • CuraCell Deep Research, Section 2.3 (CMC and Compliance Burden)
    • Paul-Ehrlich-Institut CTA approval, August 2025

  4. Predicting batch variability before it costs a patient dose

    Each biopsy presents a different starting cell population, and the variability of heavily pre-treated patients means some batches diverge from the expected expansion trajectory without an early signal.

    A digital twin of the CytoPLY expansion that takes initial biopsy metrics as inputs and predicts the expected trajectory lets the CMC team flag batches that are off-track before viability is compromised.

    • Per-Henrik Holmqvist (Head of CMC), on process variability
    • CuraCell Deep Research, Section 6.2 (IT/OT Convergence at Zellwerk)

  5. Identity-based security across the partner network

    Proprietary TCR sequencing data and CytoPLY protocols move between Solna, Berlin-Brandenburg and the IKF clinical site through different systems held by different organisations, with no single identity model governing access.

    A Zero Trust (continuous-verification, never-trust-by-default) architecture with IEC 62443 (the international standard for industrial cybersecurity) zones across the partner network gives the same access rules and audit trail wherever the data sits, which is what IP protection across the network actually depends on.

    • CuraCell Deep Research, Section 8.1 (Zero Trust for the Partner Network)
    • EQT Foundation portfolio mandate

What we'd propose

  • Enterprise AI

    Industrial data platform across Solna, Berlin-Brandenburg and Frankfurt

    An ontology-based platform that maps bioreactor parameters, sequencing output and clinical outcomes onto shared classes for patient, sample, run and time point, so that data from the three sites is queryable as one record per patient.

    • Shared data model for patient, sample and run

      One agreed vocabulary across sites

      Define patient, biopsy, manufacturing run, QC result and clinical outcome as explicit entities with agreed relationships, so a query written once returns comparable answers from Solna, Berlin-Brandenburg and Frankfurt instead of three dialects of the same table.

    • Pipelines from bioreactor control and sequencing instruments

      Three sites, one ingestion layer

      Build ingestion for Zellwerk bioreactor tags, Karolinska sequencing output and the Frankfurt clinical data system, with schema validation at each boundary so bad records fail loudly rather than enter the longitudinal record.

    • Five-year cohort query view

      Longitudinal questions answered directly

      Expose the harmonised model through a cohort query view so the CSO's five-year TCR persistence analysis is a single query against the combined data, instead of a hand-built spreadsheet pulled from three sites.

    • The five-year longitudinal question becomes a single query rather than a manual join.
    • New sites or instruments connect to the existing model instead of adding another silo.
    • Manufacturing, research and clinical teams see the same patient record at the same time.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Live monitoring of T-cell expansion at the CDMO partner

    A secure, read-only data path from Zellwerk's perfusion bioreactor control systems into a monitoring view in Solna, so CuraCell's process and CMC teams can follow a batch as it runs without operating the partner's plant.

    • Read-only connectivity to the partner control system

      Agreed tag set, no inbound control

      An edge connection at the Zellwerk site publishes an agreed set of process tags outward only, with no inbound control path. Scope, retention and access are fixed in the data agreement with the partner.

    • Run view against reference runs

      Current batch against historical envelope

      Perfusion parameters such as pH, dissolved oxygen, temperature, agitation and cell density are shown against reference batches from earlier runs, so a divergence from the expected envelope is visible while the cells are still expanding.

    • Deviation alerts to the CMC team

      Notify before batch release

      Threshold and trend rules notify the Head of CMC in Solna when a parameter leaves its expected band, with the batch context needed to open a conversation with the partner site on the same day.

    • Patient scheduling decisions are taken against the running batch, not the previous batch's report.
    • Root-cause work on a deviation starts from recorded process data rather than from reconstructed timelines.
    • Manufacturing visibility scales with cohort size without CuraCell building or staffing its own plant.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Electronic batch records and LIMS for Annex 11 readiness

    Integration work that takes results from quality control instruments and the manufacturing batch record into a single electronic batch record with electronic signatures and an audit trail that holds up under PEI inspection.

    • QC instrument integration

      Results captured at the source

      Connect sterility testing, cell viability analysis and TCR sequencing output so that results arrive in the LIMS (Laboratory Information Management System) with instrument identity, method version and timestamp attached, rather than being read off a screen and retyped.

    • LIMS to batch record data flow

      Lab result to batch record

      Map the LIMS sample and result records onto the manufacturing batch record so a release decision traces back to the specific analytical run that produced each number.

    • Annex 11 audit trail and electronic signatures

      Evidence chain stands on its own

      Implement electronic signature, versioning and audit-trail handling to EU GMP Annex 11 (the EU rule on computerised systems in GMP) and GAMP5 (Good Automated Manufacturing Practice), so the evidence chain stands on its own during a PEI inspection.

    • Fewer manual transfers between the lab and the batch record, and fewer of them to verify.
    • Inspection questions are answered from the record itself rather than from a reconstruction.
    • Release waits on the analytical result, not on the paperwork that follows it.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Zero Trust security across the partner network

    An identity-based security architecture spanning CuraCell in Solna, Zellwerk in Berlin-Brandenburg and the Frankfurt clinical site, so that access to TCR sequencing data and CytoPLY protocols follows the same rules wherever the data sits.

    • Identity-based access control

      Verify on every request

      Continuous-verification architecture where every data access request is authenticated regardless of network location, replacing implicit trust in the partner network with identity-based authorisation tied to the role of the requester.

    • IEC 62443 zoning across the partner network

      Industrial security baseline

      Define security zones and conduits between Solna, Berlin-Brandenburg and Frankfurt against IEC 62443 (the international standard for industrial cybersecurity), so that manufacturing data in transit carries the same protection as data at rest in the corporate network.

    • Secure connectivity for legacy instruments

      Closed network path to older kit

      Provide a closed connectivity solution for legacy sequencing and analysis instruments at Karolinska that were not designed for modern network exposure, enabling data acquisition without placing the device directly on the internet.

    • TCR sequencing and CytoPLY protocols carry the same protection wherever they travel in the partner network.
    • Cross-border data exchange is auditable end to end under one identity model.
    • Legacy instruments contribute data without becoming an exposed endpoint.

    We've done this before

    See how we do Enterprise AI
  • Agents

    AI agents for regulatory and quality documentation

    Narrow, reviewable agents that take the repetitive part of document work for the Phase I/IIa trial: drafting deviation summaries and periodic-review sections from source records, checking a document against its template before review, and finding every controlled document a standards change touches. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a deviation report, change-control summary or periodic-review section directly from the underlying LIMS and batch records, so the author edits and judges rather than assembles the document from scratch.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and the site's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact search across the document set

      Which documents a change touches

      When a standard, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one of the change.

    • Review queues move faster because documents arrive complete.
    • The scope of a standards change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what CuraCell AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 30 → 85
Sequencing, bioreactor and clinical data sit in separate systems across three countries with no agreed batch or patient identifier; the longitudinal question depends on building a shared model.
Process Automation 35 → 80
Visual inspection and manual transfers dominate at the partner site; closed-loop bioreactor monitoring with computer vision is the practical step toward more autonomous expansion.
Regulatory Compliance 40 → 90
The PEI CTA approval in August 2025 starts an inspection cadence that treats paperless electronic batch records and Annex 11 validation as the expected baseline.
Cybersecurity 25 → 85
Three sites and two external partners handle the same proprietary data under separate access models; a single identity-based framework is the foundation for IEC 62443 conformance.
Operational Visibility 30 → 80
Batch progress at the CDMO partner is communicated after the run; live monitoring becomes practical as soon as a read-only data path is agreed.
Sustainability Tracking 20 → 70
Cleanroom and cryopreservation dominate the energy footprint, and the EQT Foundation mandate expects per-process visibility rather than periodic reporting.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of July 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with CuraCell AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].